Degree in Chemistry, Master in Information Technology, MBA Cambridge University Judge Business School
Derek Jones is Chief Executive of the Babraham Research Campus Ltd, which develops and manages the Babraham Research Campus. Derek’s wealth of experience includes over 25 years' in the life-science industry as both a scientist and in business development and corporate development, with first-hand experience of establishing biomedical ventures.
Initially a medicinal chemist with Merck, Derek moved into business and corporate development at Chiroscience, (one of the UK first biotech companies which grew from 17 staff to a FTSE 100 company), successfully negotiating and managing several multi-million pound licensing agreements, (Bristol-Myers Squibb, Purdue Pharma, Mariushi) including being part of the team that licensed the UK’s first biotech product, Chirocaine.
In 2000, he co-founded his first company, BioWisdom, an IT/Drug discovery company. Derek was appointed COO at DanioLabs in 2002, a therapeutics company using zebrafish as a model organism for drug discovery, where he grew the company from 4 to 34 employees and raised around £10 million for VC backed companies, before selling DanioLabs to Vastox, (now Summit Plc), for £15 million in 2007.
He joined Babraham Bioscience Technologies Ltd (BBT) in 2008 as Chief Business Officer with responsibility for the knowledge exchange and commercialisation (KEC) of the Babraham Institute’s intellectual property portfolio. During that time he spun out Crescendo Biologics whose business is focussed around intellectual property from the Babraham Institute.
Derek has been a member of the BBT board since October 2008 and became CEO of BBT in 2010. Following restructuring of the business in 2013, BBT’s primary focus has been on the development and management of the campus, with KEC responsibilities returning to the Babraham Institute.
Derek has a 1st degree in Chemistry, a Master in Information Technology, and an MBA as the first cohort of the Cambridge University Judge Business School MBA programme, and is a Chartered Director. He is a non-executive director at Rothamsted Enterprises and One Nucleus. He also sits on the Cambridge University Enterprise Investment Committee.